Clinical trials: GI Tract Disorders
Breast Cancer
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria…
- Trial name
- NCT02696759
- Testing
- Blood & Fecal Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arkansas
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms, Gastrointestinal Tract
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
- Trial name
- NCT00526669
- Testing
- Lapatinib and Capecitabine
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue G3215 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.
- Trial name
- NCT02692040
- Testing
- G3215
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Obesity
A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and which stop eating. One of these chemicals is known as "Pancreatic Polypeptide" (PP).
- Trial name
- NCT01052493
- Testing
- PP 1420
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hypertriglyceridemia, Inflammation
Impacts of Lentils on Metabolism and Inflammation
The overall goal of this investigation is to determine gut microbiome dependent and independent impacts of pulse consumption on metabolic resilience and metabolic risk profiles for type 2 diabetes (T2D) and cardiovascular disease…
- Conditions
- Hypertriglyceridemia, Inflammation, Waist, Hypertriglyceridemic
- Trial name
- NCT04283448
- Testing
- Dietary Lentil, Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Montana State University
Respiratory Tract Infections, Gastrointestinal Diseases
Probiotics and Infections in Conscripts in Military Service
The aim was to study whether probiotic intervention has an impact on seasonal occurrence of upper respiratory and gastrointestinal infections in two different conscript groups.
- Conditions
- Respiratory Tract Infections, Gastrointestinal Diseases, Asthma Exacerbations
- Trial name
- NCT01651195
- Testing
- Probiotic
- Where
- 2 sites in Finland
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
End-Stage Renal Disease, Gut Microbiome Dysbiosis
Gut Microbiome and p-Inulin in Hemodialysis
The Microbiome trial is a non-randomized, open-label, sequential, multi-center study of p-inulin for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- NCT02572882
- Testing
- p-inulin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Short Gut Syndrome
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure
Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods.
- Trial name
- NCT04604275
- Testing
- Sucrase
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Miami
Fatty Liver, Nutritional and Metabolic Disease
Low GI Diet Effects on Non-Alcoholic Fatty Liver Disease
A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with…
- Trial name
- LGI-NAFLD (NCT04415632)
- Testing
- low glycemic index diet, High glycemic index diet
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Obesity, Overweight
Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals
This study evaluates the impact of increased intake of fruits and vegetables and whole grains on markers of inflammation and gut microbial composition.
- Trial name
- NCT02602496
- Testing
- Fruits and Vegetables, Whole Grain, Control
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Nebraska Lincoln
Metastatic Melanoma
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
This study is designed to evaluate the safety and tolerability of treatment with oral microbiome study intervention (SER-401) or matching placebo in combination with anti-programmed cell death 1 (anti-PD-1) therapy (nivolumab) in…
- Trial name
- MCGRAW (NCT03817125)
- Testing
- Vancomycin pretreatment, Nivolumab, SER-401
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Parker Institute for Cancer Immunotherapy
Haematological Malignancy
Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation
Malnutrition is common after haematopoietic stem cell transplantation (HSCT), and is a well-known prognostic factor for survival.
- Trial name
- NCT05460013
- Testing
- Traditional Control, Oral Nutritional Supplement
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Obesity
Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
We propose to study both stool and urine energy loss in 24 individuals on two experimental diets (50% increased and 50% reduced nutrient load relative to body size) in a random cross-over design.
- Trial name
- NCT02037295
- Testing
- Vancomycin, Overfeeding diet (OF), Underfeeding diet (UF)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Iron-deficiency
Prebiotic GOS and Lactoferrin With Iron Supplements
The ultimate goal of this research is to develop a means to safely administer iron supplements to infants in settings with a high infection burden.
- Trial name
- NCT03866837
- Testing
- Galacto-oligosaccharides, Bovine lactoferrin, Multiple micronutrient powders with 5 mg iron
- Where
- 2 sites in Kenya, Switzerland
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV
Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
The project presented here will be the first prospective, randomized evaluation of the effect of ART on the structure and function of the gut microbiome.
- Trial name
- NCT03029689
- Testing
- Raltegravir, Current ART
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Prader-Willi Syndrome, Obesity
Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding…
- Trial name
- PWSGUT (NCT05541003)
- Testing
- NBT-NM108
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey